OLIMINA3® CLINICAL STUDY
MEDICALLY FORMULATED AND CLINICALLY TESTED
The objective of the OLIMINA3® clinical study was to demonstrate that it could reduce CRP levels in women who had overcome breast cancer.. For this, a clinical study of OLIMINA3® has been carried out in 45 patients from the hospitals of La Paz, Ramón y Cajal, Puerta de Hierro and the Quirón group. This research was conducted in collaboration with physicians from Duke University in the United States.
OLIMINA3® clinical study,
carried out in 45 breast cancer patients.
La Paz, Ramón y Cajal, Puerta de Hierro, Quirón and Quirón Hospitals
Sanitas La Moraleja.
The results have shown a decrease in Reactive Protein (CRP) levels in blood and, therefore, an improvement in patients’ well-being.
.
40% PAIN REDUCTION IN BREAST CANCER PATIENTS*.
– 40% reduction in the Pain Intensity Index, statistically significant.
– Clinically relevant decrease in ALL pain parameters and pain intensity index.
– The reduction amounts to 4 points.
STATISTICALLY SIGNIFICANT DECREASE IN PCR
AND MAINTAINED OVER TIME
– 46 patients with CRP data. 70% had a decrease in CRP.
– Average decrease of 35% in CRP, statistically significant (p = 0.007).
– Reduction of CRP in all patient subgroups. The higher the CRP, the greater the reduction.
– Higher CRP level (cut-off level 2.5x), reduction of -> 47% in CRP, being significant on d30 (p = 0.03) and on d60 (p = 0.04).
Conclusions of the clinical study
Preclinical study
Preclinical in vitro* studies conducted by PHYTOGEN MEDICAL FOOS and its partners to determine the efficacy of HYTOLIVE®, have shown impressive results. All of these are consistent with the evidence from animal and human trials.
It has been shown that the polyphenols in extra virgin olive oil, contained in HYTOLIVE®, can help the body’s response to diseases caused by inflammatory processes*.
Preclinical research conducted with our ingredients has shown that HYTOLIVE® it inhibits the production of ROS (reactive oxygen species) by smooth muscle arterial cells, inhibits LDL oxidation and induces apoptosis 5 times more than the control vehicle in 3 of the 8 cell lines tested.
Journal of Clinical Oncology
Breast cancer patients with higher levels of inflammatory proteins in the blood (CRP) were 2-3 times more likely to die than those with lower levels (n = 734).5
Cleveland Clinic
According to the Cleveland Clinic, the Harvard Women’s Health Study showed that high CRP levels were more predictive of coronary heart disease and stroke in women who had high cholesterol levels.6
Women’s Hospital and Brighan
The Brigham and Women’s Hospital study concludes: Reducing inflammation without reducing cholesterol reduces the risk of cardiovascular events. published in New England Journal of Medicine, August 2017.8
Breast Cancer Research
Elevated CRP levels are associated with reduced overall and disease-free survival and increased risk of death (n = 2,910).9